Skip to Main Content

Paper Details

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Clin Cancer Res
0
2024
9-ING-41, Elraglusib, GSK-3b, Patients, acute T-cell leukemia/lymphoma, advanced malignancies, carboplatin, doxorubicin, elraglusib, fatigue, gemcitabine, glycogen synthase kinase-3b, hematologic malignancies, irinotecan, lomustine, melanoma, nab-paclitaxel, paclitaxel, patient, patients, pemetrexed, solid tumors
Author NameAffiliation
Hu LiMayo Clinic
Neeltje SteeghsThe Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital
  • 1 - 2

Datasets

Release 1.2